Skip to main content
SpringerLink
Log in

Newer HCV treatments cost effective in most patients in US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

References

  1. Najafzadeh M, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Annals of Internal Medicine 162: 407-19, No. 6, 17 Mar 2015. Available from: URL: http://doi.org/10.7326/M14-1152.

    Article  PubMed  Google Scholar 

  2. Chhatwal J, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Annals of Internal Medicine 162: 397-406, No. 6, 17 Mar 2015.

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Newer HCV treatments cost effective in most patients in US. PharmacoEcon Outcomes News 724, 21 (2015). https://doi.org/10.1007/s40274-015-1999-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-1999-8

Search

Navigation